Aquestive Therapeutics, Inc.
AQST · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $44.5M | $57.6M | −22.6% |
| Operating income | −$71.0M | −$30.8M | −131% |
| Net income | −$83.8M | −$44.1M | −89.8% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $7.60M | $12.8M | −40.6% |
| Operating income | −$14.5M | −$11.5M | −26.1% |
| Net income | −$16.5M | −$15.4M | −7.1% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Aquestive's revenue in FY2025?
- $44.5M in FY2025 (Fiscal year ended Dec 31, 2025), −22.6% vs $57.6M a year earlier, per its 10-K filed Mar 2026.
- Was Aquestive profitable in FY2025?
- No: net income was −$83.8M and operating income −$71.0M in FY2025.
- What was Aquestive's revenue in Q3 2026?
- $7.60M (−40.6% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.